Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CMV-CD19 CAR T-cells | CD19 Immune Cell Therapy 64 | CMV-CD19 CAR T-cells are CMV-specific T-cells that are engineered to express a chimeric antigen receptor (CAR) targeting CD19, which may stimulate an anti-tumor response against CD19-expressing tumors (PMID: 35027426, PMID: 25838392). | ||
Multi-antigen CMV-modified vaccinia Ankara vaccine | CMV-MVA Triplex Vaccine|CMV-Modified Vaccinia Ankara Vaccine | Multi-antigen CMV-modified vaccinia Ankara vaccine is viral-based vaccine engineered to express three cytomegalovirus (CMV) antigens, which may induce a CMV-specific immune response (PMID: 27760761, PMID: 35272066). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06735690 | Phase I | CMV-CD19 CAR T-cells CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine | Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia | Not yet recruiting | USA | 0 |
NCT05801913 | Phase I | CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |